NCT06851403Enrolling by invitation
The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study
The Effectiveness and Safety of Dupilumab in Children with Severe Asthma in China: a Real-world Study
Source: ClinicalTrials.gov · Last updated 28 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 213 (estimated)
- First submitted
- 3 Oct 2024
- Start date
- 30 Jan 2022
- Primary completion date
- 30 Dec 2025
- Lead sponsor
- Guangzhou Institute of Respiratory Disease
- Diseases
- Asthma
- NCT number
- NCT06851403
What you commit to
- Study type: Observational
- Planned participants: 213
- From 30 Jan 2022 to the primary completion date, 30 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with conditions other than asthma receiving treatment with dupilumab, individuals currently using other biologics or undergoing sublingual or subcutaneous immunotherapy, active parasitic infections, and children with immunodeficiency were excluded.
Who the study is looking for
- Enrolled patients were required to have been on regular ICS-LABA therapy for at least 3-6 months without adequate control. The attending physician evaluated these patients as having type 2 inflammatory asthma based on factors such as FeNO (fractional exhaled nitric oxide) levels ≥ 20, sputum eosinophils (EOS) percentage ≥ 2%, and/or blood EOS count ≥ 300/μl. All children were prescribed with dupilumab during the study period.
Age in the registry: 4 years to 16 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Guangzhou Institute of Respiratory Disease Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.